Cercar
01/11/2025
Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021
Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).
01/11/2025
Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus
Casasayas, M, Holgado, A, León, X, Kolanczak, K, Pérez-Sempere, M, Quer, M, Gras-Cabrerizo, JR. Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus. JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2025; 139(11)DOI:10.1017/S0022215125102958. PMID:40734309. IF:0.800(Q3/8D).
01/11/2025
First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup))
Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).
01/11/2025
Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024
Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).
01/11/2025
CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas
Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).
01/11/2025
Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy
Farré, A, Huguet, J, Basile, G, Diéguez, L, Izquierdo, P, Sánchez, R, Gavrilov, P, Gallioli, A, Faba, OR, Gaya, JM, Palou, J, Breda, A. Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy. Actas Urologicas Espanolas. 2025; 49(9)DOI:10.1016/j.acuro.2025.501834. PMID:. IF:1.200(Q3/7D).
01/11/2025
Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort
Baboudjian, M, Leni, R, Oderda, M, Peyrottes, A, Kesch, C, Al-Nader, M, Uleri, A, Dariane, C, Baud, H, Olivier, J, Rios, AR, Sanguedolce, F, Benard, V, Windisch, O, Valerio, M, Gandaglia, G, Ploussard, G. Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. European Urology Oncology. 2025; 8(5)DOI:10.1016/j.euo.2025.01.009. PMID:39965999. IF:9.300(Q1/1D).
01/11/2025
Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study
Downes, MR, Lajkosz, K, Algaba, F, Allory, Y, Amin, MB, Cheng, L, Desai, S, Eckstein, M, Hartmann, A, Lopez-Beltran, A, Mannweiler, S, van Montfoort, ML, Oxley, J, Paner, GP, Samaratunga, H, Shen, S, Warrick, J, Williamson, SR, Wobker, SE, van der Kwast, TH. Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study. HISTOPATHOLOGY. 2025; 87(5)DOI:10.1111/his.15438. PMID:40058790. IF:4.100(Q1/1D).